**PERSPECTIVE**

Internet tools to enhance breast cancer care

Shlomit Strulov Shachar1,2 and Hyman B Muss1

Internet tools have become a great aid in the daily practice of physicians who treat breast cancer patients. In cancer care there are frequent and important intersections where major decisions need to be made; these include (1) whether or not to give chemotherapy; (2) how much toxicity to expect, and (3) the life expectancy of the patient, considering non-breast cancer comorbidities. These decisions can be made more accurately using calculators based on data sets of thousands of patients as opposed to physician intuition. Such tools also help patients and caregivers in optimal decision making, as they estimate the absolute benefits and risks of treatment. In this perspective we describe selected internet sites that are useful across several domains of care, including the potential benefits of different adjuvant regimens for early breast cancer, prognosis after neoadjuvant therapy, prognosis for ductal carcinoma in situ, and toxicity and life expectancy estimates. We review the variables required to use the tools, the results obtained, the methods of validation, and the advantages and disadvantages of each tool.

**INTRODUCTION**

In the past decade there has been increased usage of online tools to determine the value of adjuvant systemic therapies for breast cancer—including neoadjuvant therapy—to estimate life expectancy, to predict outcomes for patients with ductal carcinoma in situ (DCIS) based on the varied treatment options, and to estimate chemotherapy-related toxicity in older patients. Having an accessible online tool that can estimate and personalize the benefits of different treatment outcomes for individual patients has become a great help in daily practice. There are currently many resources available; this perspective will focus on several which we feel are most helpful. In addition to describing the strengths and weaknesses of each tool’s application, we will discuss how they were validated. A detailed list of our preferred sites is shown in Table 1.

Tools for systemic adjuvant therapy

**Adjuvant!**. Adjuvant! (https://www.adjuvantonline.com/) is a groundbreaking program that is probably the most widely used tool for estimating the benefits of adjuvant endocrine therapy and chemotherapy.1 The tool assesses individual patient risk of recurrence and death at 10 years. Mortality risk is based on surveillance, epidemiology, and end-results (SEER) data for women aged 36–69 years, and estimates of the efficacy of adjuvant therapy from data from the Early Breast Cancer Trialists’ Collaborative Group. Entering information on age and selected tumor characteristics (tumor size and grade, number of positive axillary nodes, and hormone receptors status) allows for prediction of the 10-year risk of relapse-free and overall survival. A strength of this tool is that one can add a rough estimate of the effect of comorbidity on survival to the model. This allows the clinician to determine the benefits of treatment when patients have major competing causes of mortality—in addition to their breast cancer mortality risk. Adjuvant!’s strength also lies in the fact that it provides details on deaths from both breast cancer and non-breast cancer causes. This latter information is especially important in older patients, for whom 10-year mortality is frequently dominated by non-breast cancer related events.

Despite these strengths, Adjuvant! has several limitations. The relapse estimates include local-regional recurrence as well as distant metastases; this is important as the proportions of both may vary greatly depending on stage and tumor phenotype. In addition, data from SEER were not available for HER-2 status, and the benefits of adjuvant trastuzumab are not available in this model. Validation also poses a problem, as some studies of the model have not been consistent. Although a Dutch study confirmed the accuracy of the tool in the European population (N = 5380),2 a British study (N = 1065) found that in a high percentage of patients survival was overestimated.2,3 Another validation in an elderly population (N = 2012) showed there was an overestimation of the added value of chemotherapy for older patients and those younger than 40 years.2,4

**PREDICT**. The PREDICT tool (http://www.predict.nhs.uk/) was developed using cancer registry data from 5,694 patients in the UK.5 Validation of the model was made on 5,000 other patients from the U.K. and 3140 patients from Canada.6 An estimation of therapy and prognosis of HER 2 tumors was later incorporated.7 The PREDICT tool utilizes data on patient age and tumor characteristics (the mode of detection (i.e., screening versus discovery of a palpable mass), size, grade, ER status, and Ki67 status) to provide a choice for estimating the value of endocrine therapy alone, or endocrine therapy and second-generation chemotherapy (antracycline-containing, > 4 cycles or equivalent) versus third-generation (taxane-containing chemotherapy regimens).8 The predict model allows one to estimate the effects of adjuvant endocrine and chemotherapy treatment on survival at 5 and 10 years, but there is no estimate of relapse and it does not account for non-breast cancer causes of mortality in the overall survival estimate. However, unlike Adjuvant!, the PREDICT model can estimate the benefits of anti-HER2 therapy in patients with HER-2 positive tumors.7

1Lineberger Comprehensive Cancer Center, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA and 2Division of Oncology, Rambam Health Care Campus, Haifa, Israel.

Correspondence: HB Muss (muss@med.unc.edu)

Received 17 February 2016; accepted 18 February 2016
addition, a recent study has validated this tool’s ability to provide accurate estimates of the potential benefits of treatment at 5 years for older patients.9 Table 2 provides several scenarios showing the effects of treatment selection on survival using the PREDICT model.

CancerMath. CancerMath (http://www.lifemath.net/cancer/breastcancer/therapy/) utilizes tools that estimate the probability of having positive lymph nodes (based on age and tumor characteristics), breast cancer mortality, and the potential benefits of treatment with endocrine therapy and chemotherapy. Estimates are based on SEER data (N=362,491) and include HER-2 status, tumor size, nodal involvement, tumor phenotype, and grade.10

Oncotype DX. The Oncotype DX website (https://online.genomichealth.com/Login.aspx) provides two diagnostic tools that analyze recurrence scores and take into account the type of endocrine therapy (tamoxifen or an aromatase inhibitor) as well as patient age, tumor size, and tumor grade, to further refine the estimates of endocrine

| Table 1. Web sites for breast cancer care |
| --- |
| **Name** | **Details** | **URL/Link** |
| **Breast cancer predictive websites** | | |
| Adjuvant! (adjuvantonline.com) | Calculate benefits of adjuvant therapy for patients with breast cancer. Can add estimates of comorbidity to calculations. Registration and password needed. | https://www.adjuvantonline.com/ |
| CancerMath | Several tools for predicting survival at 15 years, estimating therapy benefit. | http://www.lifemath.net/cancer/breastcancer/therapy/ |
| DCIS Recurrence Memorial Sloan Kettering | A tool for patients who had BCS for DCIS to predict the likelihood that their breast cancer will return in the same breast that was originally treated. | http://nomograms.mskcc.org/breast/ DuctalCarcinomaInSituRecurrencePage.aspx |
| PREDICT | UK-derived tool which calculates benefits of adjuvant therapy for patients with breast cancer. Does not allow for comorbidity. Can calculate benefits for patients with HER-2-positive tumors. | http://www.predict.nhs.uk/ |
| Oncotype DX® tools | Tools to understand how hormonal therapy and pathological and clinical factors can be assessed with the Oncotype DX® Breast Cancer Assay Recurrence Score result. Registration and password needed. | https://online.genomichealth.com/Login.aspx |
| Neoadjuvant Therapy Outcomes Tool MD Anderson Cancer Center | Calculates the anticipated 5-year distant metastasis-free survival and disease-specific survival for breast cancer patients following treatment with neoadjuvant chemotherapy. Pathological response also integrated. | http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=bcnt |
| **Life expectancy prediction and geriatric oncology websites** | | |
| ASCO University | A series of online modules that explore different care options for older patients, including those with breast cancer. Also has MOC course on geriatric oncology. | http://university.asco.org/geriatric-oncology |
| CARG (Cancer and Aging Research Group) | A group of researchers with major interest in geriatric oncology research. Opportunities for mentoring. Website includes online chemotherapy toxicity tool and geriatric assessment tools. | http://www.mycarg.org/ |
| ePrognosis | A series of tools based on systematic review of literature that allows for estimation of life expectancy in older adults. | http://epronosis.ucsf.edu/default.php |
| International Society of Geriatric Oncology (SIOG) | International organization that focuses on geriatric oncology. Website has useful links to geriatric oncology guidelines and other educational materials. | http://www.siog.org/ |
| **Toxicity prediction websites** | | |
| Moffitt Cancer Center Senior Adult Oncology Program Tools CARG (Cancer and Aging Research Group) | Online tools for estimating chemotherapy toxicity (CRASH score) and other geriatric tools Online chemotherapy toxicity tool and geriatric assessment tools. | http://moffitt.org/cancer-types--treatment/cancers-we-treat/senior-adult-oncology-program-tools http://www.mycarg.org/ |

Abbreviations: ASCO, American Society of Clinical Oncology; BCS, breast-conserving surgery; CRASH, chemotherapy risk assessment scale for high-age patients; DCIS, ductal carcinoma in situ; HER2, human epidermal growth factor receptor 2; MOC, Maintenance of Certification; UK, United Kingdom.
therapy on 10-year metastases-free survival. This can result in small but potentially important changes in our understanding of metastatic relapse risk, and could help physicians make the decision of whether to offer chemotherapy. This combined score has resulted in classifying fewer patients as intermediate risk (17.8% vs 26.7%, P < 0.001) and more patients as lower risk (63.8% vs 54.2%, P < 0.001).

Neoadjuvant chemotherapy outcomes tool. The neoadjuvant chemotherapy outcomes tool (http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=bcnt) provides estimates of 5-year distant metastases-free and disease-specific survival after neoadjuvant treatment, and incorporates initial clinical stage before treatment, post-neoadjuvant pathological stage, estrogen receptor status, and nuclear grade.

Tools for treatment outcomes for patients with ductal carcinoma in situ
An online tool, the ‘Breast Cancer Nomogram: Ductal Carcinoma In Situ (DCIS) Recurrence’ has been developed at the Memorial Sloan Kettering Cancer Center (http://nomograms.mskcc.org/breast/DuctalCarcinomaInSituRecurrencePage.aspx) to predict in-breast recurrence risk after breast-conserving surgery. The program, takes into account many patient and tumor characteristics, including age, family history, presentation, tumor grade, presence of necrosis, surgical margins, year of surgery, and number of excisions, as well as the potential risk-reducing benefits of adjuvant breast irradiation and/or endocrine treatment. It provides both the 5- and 10-year probability of in-breast recurrence. This can be especially helpful to patients and physicians, since mortality with this diagnosis is extremely low and many patients may elect to forego radiation and endocrine treatment after reviewing the potential risks and benefits of each modality.

Tools for predicting life expectancy

Eprognosis. The use of chronological age to predict life expectancy in older patients should be discouraged

| Table 2. Survival benefit of adjuvant treatment in breast cancer by PREDICT |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                             | Patient 1 | Patient 2 | Patient 3 | Patient 4 |
| Patient and tumor characteristics |          |          |          |          |
| Age                         | 42        | 55        | 72        | 38        |
| Mode of detection           | Symptomatic | Screening | Symptomatic | Symptomatic |
| Tumor size (mm)             | 18        | 15        | 40        | 32        |
| Tumor grade                 | 3         | 2         | 2         | 1         |
| Number of positive lymph nodes | 3          | 0         | 2         | 1         |
| Estrogen Receptor status    | Negative  | Positive  | Positive  | Negative  |
| HER2 status                 | Positive  | Negative  | Negative  | Negative  |
| Ki 67 status                | Positive (> 10%) | Unknown | Unknown | Positive (> 10%) |
| Generation of chemotherapy regimen | Second | Third | Second | Third |
| 5-Year survival results (%) |          |          |          |          |
| No adjuvant treatment       | 60        | 96        | 76        | 61        |
| Benefit of adjuvant chemotherapy | 15 | 1 | 3 | 18 |
| Benefit of adjuvant Trastuzumab | 6 | na | na | n/a |
| Benefit of adjuvant hormone therapy | na | 1 | 4 | n/a |
| Total survival with adjuvant therapy | 81 | 98 | 83 | 79 |
| 10-Year survival results (%) |          |          |          |          |
| No adjuvant treatment       | 49        | 90        | 50        | 49        |
| Benefit of adjuvant chemotherapy | 18 | 1 | 5 | 22 |
| Benefit of adjuvant Trastuzumab | 5 | na | na | n/a |
| Benefit of adjuvant Hormone therapy | na | 2 | 9 | n/a |
| Total survival with adjuvant therapy | 72 | 93 | 64 | 71 |
| Abbreviations: HER2, human epidermal growth factor 2. *Presented with palpable mass; data modified from PREDICT. **|

| Table 3. Four and 10-year survival using combined Lee-Schonberg calculator in ePrognosis |
|--------------------------------|-----------------------------|-----------------------------|
| Variable                                    | Patient 1 | Patient 2 |
| Age                                         | 75–79 Years | 65–69 Years |
| Gender                                      | Female | Female |
| BMI                                         | ≥ 25 | ≥ 25 |
| Patient’s self-reported health              | Excellent | Poor |
| Chronic lung disease                        | No | No |
| Prior cancer                                | No | No |
| Congestive heart failure                    | No | Yes |
| Diabetes or high blood sugar                | No | Yes |
| Describe cigarette use                      | Never smoked | Current smoker |
| Difficulty walking a quarter mile without help | No | Once |
| Overnight hospitalization in past 12 months | No | No |
| Help in routine daily activities            | No | No |
| Memory problems interfering with managing finances | No | No |
| Memory problem interfering with bathing or showering | No | No |
| Difficulty pushing or pulling large objects | No | Yes |
| Estimated 4-5-year survival                 | 96% | 77% |
| Estimated 10-year survival                  | 81% | 24% |

Abbreviation: BMI, body mass index. Data modified from www.eprognosis.org.
Toxicity-risk calculators for older patients
CARG. The Cancer and Aging Research Group (CARG) (http://www.mycarg.org) has developed a toxicity-risk calculator based on data from 500 patients with a variety of both early and late stage cancers. The calculator allows for prediction of grades 3–5 toxicities16 and the model includes standard clinical variables (gender, age, weight, height, serum creatinine, hemoglobin level, cancer type, chemotherapy treatment (dosage), and single agent or combination chemotherapy) as well as six variables attained via a short geriatric assessment (hearing status, number of falls, hearing problems, ability to take medications, ability to walk one block, and social activities limitations due to health or emotional problems). From these entries one can calculate a risk score that not only can reasonably predicts severe toxicity, but also is superior to performance status, a poor predictor.17

CRASH (Chemotherapy-risk assessment scale for high-age patients). CRASH (http://moffitt.org/cancer-types–treatment/cancers-we-treat/senior-adult-oncology-program-tools) is a user-friendly tool to estimate the risk of severe chemotherapy toxicity based on the specific chemotherapy regimen, diastolic blood pressure, instrumental activities of daily living, lactate dehydrogenase, performance status, mini-mental status, and a mini-nutritional assessment. This tool was developed and validated on a cohort of cancer patients 70 years and older (N = 512).18

Conclusions
The tools we have discussed are readily available for use in daily practice and office staff can be trained to use these models and provide information to busy clinicians. Most of them have a user-friendly interface and can be used without registration and a password, which is a great advantage on a busy day. The tools used for assessing the benefits of adjuvant systemic therapy and the management of DCIS are frequently used in patients who have had tumor tissues sent for newer genetic-based assays. Such assays may provide more detailed information, especially in patients with node-negative, hormone receptor-positive, and HER-2-negative breast cancers,19–23 and in many patients the estimates from genetic-based assays are more appropriate for decision making.

The internet has given us the ability to rapidly use key clinical information at the point of patient contact to help make treatment decisions. The tools discussed in this review give physicians the opportunity to obtain relatively precise, up to date estimates of treatment effect, longevity, and toxicity that are likely to be more accurate than decisions made on intuition and experience alone. It is important, however, that those who have developed these tools and who will develop new tools in the future continually re-validate each tool as new data become available and make appropriate modifications as needed.